Kos Biotechnology Partners: Four new investments by the end of 2026

The fund has raised €111 million. Its investment strategy, portfolio companies and plans for a biotechnology hub in Crete.

Kos Biotechnology Partners: Four new investments by the end of 2026

This article is an AI translation of an original piece published in Greek. Read original

Kos Biotechnology Partners is expected to announce four new investments by the end of 2026, taking the number of companies in its portfolio to nine in the fund’s first year of operation, the fund’s team said at a briefing for journalists.

The four new investments are expected to be announced in stages over the next month and a half. They involve a Boston-based company, a Greek pharmaceutical services (Pharma Services) company, an Israeli oncology company and a spin-out from Harvard Medical School founded by a Greek professor.

Capital raised and investors

Kos Biotechnology Partners, founded in 2025 by Simos Symeonidis and Alexandros Tzoukas, is Greece’s first venture capital fund focused exclusively on life sciences.

The fund has raised €111 million to date, about half of it from the Hellenic Development Bank of Investments (HDBI). Its investors also include Greece’s four systemic banks, Greek pharmaceutical companies, Greek family offices and Greek-American private investors with many years of experience in the US biotechnology sector.

Aiming to make about 20 investments in total, the fund has a 10-year term. The vast majority of its capital will be deployed in the first four years, with the remainder reserved for follow-on investments in portfolio companies. Investment tickets range from €1.5 million to €5 million per company, with an average of €3 million.

Investment strategy

The fund’s investment strategy focuses mainly on areas such as the discovery and development of new drugs (Drug Discovery), specialist services for pharmaceutical companies (Pharma Services) and TechBio, the use of technology and artificial intelligence in the biotechnology sector.

The fund invests in companies at any stage of development (stage agnostic), from very early stage through to Phase III clinical trials.

Portfolio companies

The fund has invested €20 million in the five companies currently in its portfolio: Epikast, Rezo Therapeutics, Fathom Therapeutics, Golden Age Health and the German CatalYm. With the completion of the four new investments, the total invested is expected to reach about €25 million.

Biotechnology hub in Crete

As part of efforts to strengthen the presence of its portfolio companies in Greece, Kos Biotechnology Partners has already signed a memorandum of understanding providing for the option to lease laboratories and space at the Foundation for Research and Technology – Hellas (FORTH) in Crete.

The initiative aims to bring the companies’ scientific teams together on the island and create a biotechnology innovation hub, with research and development (R&D) activities. The goal is to make use of both the existing laboratory infrastructure and modern equipment, as well as Crete’s highly skilled scientific workforce.

The creation of the hub in Crete is part of a broader plan by Kos Biotechnology Partners, with the ultimate aim of positioning Greece as an innovation hub in biotechnology.

v
Privacy